Company news
Dyadic International, Inc. news in 2024
Dyadic International, Inc.'s news releases, calls and decks from 2024, newest first.
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
November 20, 2024
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
November 11, 2024
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 3, 2024
Dyadic Expands Global Presence with Participation in Key Industry Events
October 8, 2024
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
September 22, 2024
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 12, 2024
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
June 27, 2024
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 13, 2024
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
April 29, 2024
Dyadic Reports 2023 Full Year Results and Recent Company Progress
March 27, 2024
Dyadic Announces Change in Board and Management Leadership Roles
March 27, 2024
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
March 25, 2024
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 10, 2024
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 27, 2024
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 20, 2024
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
February 12, 2024
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 5, 2024
Calls in 2024
- Dyadic International (NASDAQ:DYAI) Q3 2024 Earnings Call
Nov 12, 2024
Transcript - Dyadic International (NASDAQ:DYAI) Q2 2024 Earnings Call
Aug 13, 2024
Transcript - Dyadic International (NASDAQ:DYAI) Q1 2024 Earnings Call
May 14, 2024
Transcript - Dyadic International (NASDAQ:DYAI) Q4 2023 Earnings Call
Mar 28, 2024
Transcript